Leman Biotech, in collaboration with XtalPi Technology, has reached a significant milestone in the AI Enabled Superkine pipeline. Using the MetaAI-10 computational model and yeast demonstration technology, Leman Biotech successfully conducted high-throughput screening of superkine mutants, resulting in over 5000 immunometabolic regulators with exceptionally high affinity. Patent application (number: 2022116277856) has been filed for the invention.
.jpg)
Some of these superkine mutants and their natural receptors exhibit over 100 times higher affinity than the similar superkines reported by Stanford University in its recent publication in Science. Leman Biotech aims to apply these immunomodulatory superkines in cancer immunotherapy, advancing our Meta 10 metabolic reprogramming platform. We also plan to deepen our collaboration with XtalPi for AI drug development of innovative immunotherapies with specificity and low toxicity.
Leman Biotech's achievement in AI-enabled high-throughput screening marks a significant advancement in immunometabolic regulation research, with potential implications for cancer treatment and AI drug research and development.
